Jump to main content
Jump to site search

Issue 2, 2019
Previous Article Next Article

Peptide ligand-mediated targeted drug delivery of nanomedicines

Author affiliations

Abstract

Targeted drug delivery is emerging as a promising strategy to achieve better clinical outcomes. Actively targeted drug delivery that utilizes overexpressed receptors or antigens on diseased tissues is receiving increasing scrutiny, especially due to the uncertainty of existence of the enhanced permeability and retention (EPR) effect in cancer patients. Peptide ligands are advantageous over other classes of targeting ligands due to their accessibility of high-throughput screening, ease of synthesis, high specificity and affinity, etc. In this review, we briefly summarize the resources of peptide ligands and discuss the pitfalls and perspectives of peptide ligand-mediated targeted delivery of nanomedicines.

Graphical abstract: Peptide ligand-mediated targeted drug delivery of nanomedicines

Back to tab navigation

Publication details

The article was received on 23 Oct 2018, accepted on 31 Dec 2018 and first published on 18 Jan 2019


Article type: Review Article
DOI: 10.1039/C8BM01340C
Citation: Biomater. Sci., 2019,7, 461-471

  •   Request permissions

    Peptide ligand-mediated targeted drug delivery of nanomedicines

    Z. Jiang, J. Guan, J. Qian and C. Zhan, Biomater. Sci., 2019, 7, 461
    DOI: 10.1039/C8BM01340C

Search articles by author

Spotlight

Advertisements